Gilead Sciences, Inc.GILD
What Gilead Sciences, Inc. does.
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.
We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.
In 2025, our commercial portfolio included more than 25 therapies, including the following products and collaboration products with approved indications in the U.S.:
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $24.7B | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Net income | $123.0M | $6.2B | $4.6B | $5.7B | $480.0M | $8.5B |
| Free cash flow | $7.5B | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
More on GILD.
- Gilead Sciences, Inc. summary
- Gilead Sciences, Inc. financial statements
- Gilead Sciences, Inc. key metrics
- Gilead Sciences, Inc. health scores and style box
- Gilead Sciences, Inc. earnings
- Gilead Sciences, Inc. dividends
- Gilead Sciences, Inc. valuation
- Gilead Sciences, Inc. ownership and insiders
- Gilead Sciences, Inc. peers
Figures from Gilead Sciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.